These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
560 related articles for article (PubMed ID: 36518297)
21. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma. Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618 [TBL] [Abstract][Full Text] [Related]
22. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker. Wang Y; Liu T; Zhang K; Huang RH; Jiang L Eur J Med Res; 2023 Jul; 28(1):258. PubMed ID: 37501187 [TBL] [Abstract][Full Text] [Related]
23. Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer. Zhong H; Shi Q; Wen Q; Chen J; Li X; Ruan R; Zeng S; Dai X; Xiong J; Li L; Lei W; Deng J Front Immunol; 2023; 14():1058627. PubMed ID: 36923407 [TBL] [Abstract][Full Text] [Related]
24. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma. Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL Front Immunol; 2021; 12():781087. PubMed ID: 35069553 [TBL] [Abstract][Full Text] [Related]
25. A pan-cancer analysis uncovering the function of CRHBP in tumor immunity, prognosis and drug response: especially its function in LIHC. Chen B; Chen S; Wang X; Zhang J; Wang H; Li J; Zhang Z; Yu F; Kong W Sci Rep; 2024 Feb; 14(1):3112. PubMed ID: 38326407 [TBL] [Abstract][Full Text] [Related]
26. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
27. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma. Liu C; Zhang W; Zhou X; Liu L Front Immunol; 2022; 13():983490. PubMed ID: 36618420 [TBL] [Abstract][Full Text] [Related]
28. Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma. Liu T; Li ZZ; Sun L; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P BMC Cancer; 2023 Oct; 23(1):1007. PubMed ID: 37858061 [TBL] [Abstract][Full Text] [Related]
29. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy. Yang Q; Zeng S; Liu W PeerJ; 2023; 11():e15019. PubMed ID: 36949759 [TBL] [Abstract][Full Text] [Related]
30. DDR1 is a Novel Biomarker and Potential Therapeutic Target for the Combination Treatment of Liver Hepatocellular Carcinoma. Li T; Hu H; Song Y; Shi Y; Hu D; Shen W; Ning B Cancer Control; 2024; 31():10732748241286257. PubMed ID: 39284684 [TBL] [Abstract][Full Text] [Related]
31. ERH Impacts Patient Prognosis and Tumor Immune Microenvironment: A Pan-Cancer Analysis. Gong Q; Li Q; Shen X; Xu Z Comb Chem High Throughput Screen; 2024 Apr; ():. PubMed ID: 38584561 [TBL] [Abstract][Full Text] [Related]
32. Potential Diagnostic and Prognostic Values of CBX8 Expression in Liver Hepatocellular Carcinoma, Kidney Renal Clear Cell Carcinoma, and Ovarian Cancer: A Study Based on TCGA Data Mining. Lin J; Chen L; Wu D; Lin J; Liu B; Guo C Comput Math Methods Med; 2022; 2022():1372879. PubMed ID: 35813444 [TBL] [Abstract][Full Text] [Related]
33. Integrated Single-cell and Transcriptome Sequencing Analyses Identified PREX1 as an Immune-related Prognostic Biomarker for Liver Hepatocellular Carcinoma. Yang J; Fan LY; Shi KY Int J Med Sci; 2024; 21(8):1559-1574. PubMed ID: 38903921 [No Abstract] [Full Text] [Related]
34. WD repeat domain 43 as a new predictive indicator and its connection with tumor immune cell infiltration in pan-cancer. Yang X; Luo T; Liu Z; Liu J; Yang Z Medicine (Baltimore); 2024 Aug; 103(31):e39153. PubMed ID: 39093744 [TBL] [Abstract][Full Text] [Related]
35. FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma. Hou Y; Li J; Yu A; Deng K; Chen J; Wang Z; Huang L; Ma S; Dai X Int J Med Sci; 2023; 20(7):918-932. PubMed ID: 37324186 [No Abstract] [Full Text] [Related]
36. Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis. Xu J; Ma H; Shan B PLoS One; 2022; 17(10):e0273163. PubMed ID: 36194583 [TBL] [Abstract][Full Text] [Related]
37. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5. Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205 [TBL] [Abstract][Full Text] [Related]
38. Ferroptosis regulator SLC7A11 is a prognostic marker and correlated with PD-L1 and immune cell infiltration in liver hepatocellular carcinoma. Liang Y; Su S; Lun Z; Zhong Z; Yu W; He G; Wang Q; Wang J; Huang S Front Mol Biosci; 2022; 9():1012505. PubMed ID: 36267158 [No Abstract] [Full Text] [Related]
39. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment. Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517 [TBL] [Abstract][Full Text] [Related]
40. Systematic Analyses of the Role of the Reader Protein of Shao XY; Dong J; Zhang H; Wu YS; Zheng L Front Mol Biosci; 2020; 7():577460. PubMed ID: 33344502 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]